JP2017513904A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017513904A5 JP2017513904A5 JP2016564173A JP2016564173A JP2017513904A5 JP 2017513904 A5 JP2017513904 A5 JP 2017513904A5 JP 2016564173 A JP2016564173 A JP 2016564173A JP 2016564173 A JP2016564173 A JP 2016564173A JP 2017513904 A5 JP2017513904 A5 JP 2017513904A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- target
- igf
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 25
- 102000036639 antigens Human genes 0.000 claims 25
- 108091007433 antigens Proteins 0.000 claims 25
- 239000012634 fragment Substances 0.000 claims 17
- 239000000611 antibody drug conjugate Substances 0.000 claims 14
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 14
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 10
- -1 CD79 Proteins 0.000 claims 9
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 7
- 229940125644 antibody drug Drugs 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 3
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 3
- 108700012439 CA9 Proteins 0.000 claims 3
- 101150013553 CD40 gene Proteins 0.000 claims 3
- 102100025221 CD70 antigen Human genes 0.000 claims 3
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims 3
- 108010055196 EphA2 Receptor Proteins 0.000 claims 3
- 108010055334 EphB2 Receptor Proteins 0.000 claims 3
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 claims 3
- 102100031968 Ephrin type-B receptor 2 Human genes 0.000 claims 3
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims 3
- 101710088083 Glomulin Proteins 0.000 claims 3
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 3
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 claims 3
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims 3
- 101000893701 Homo sapiens 3-galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase FUT3 Proteins 0.000 claims 3
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 3
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 3
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 3
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims 3
- 101000881679 Homo sapiens Endoglin Proteins 0.000 claims 3
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 3
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 claims 3
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims 3
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 3
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 3
- 101001018034 Homo sapiens Lymphocyte antigen 75 Proteins 0.000 claims 3
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 3
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims 3
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 3
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims 3
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 claims 3
- 101000834948 Homo sapiens Tomoregulin-2 Proteins 0.000 claims 3
- 101000904724 Homo sapiens Transmembrane glycoprotein NMB Proteins 0.000 claims 3
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 3
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 3
- 102000003735 Mesothelin Human genes 0.000 claims 3
- 108090000015 Mesothelin Proteins 0.000 claims 3
- 102100023123 Mucin-16 Human genes 0.000 claims 3
- 101100369076 Mus musculus Tdgf1 gene Proteins 0.000 claims 3
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 3
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 3
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 claims 3
- 102100026160 Tomoregulin-2 Human genes 0.000 claims 3
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 claims 3
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 3
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 3
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 102000006495 integrins Human genes 0.000 claims 3
- 108010044426 integrins Proteins 0.000 claims 3
- 239000012528 membrane Substances 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 3
- 101150047061 tag-72 gene Proteins 0.000 claims 3
- 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 102000001301 EGF receptor Human genes 0.000 claims 2
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 claims 2
- 101000801433 Homo sapiens Trophoblast glycoprotein Proteins 0.000 claims 2
- 108090000144 Human Proteins Proteins 0.000 claims 2
- 102000003839 Human Proteins Human genes 0.000 claims 2
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims 2
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 2
- 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 claims 2
- 102100033579 Trophoblast glycoprotein Human genes 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 102000051957 human ERBB2 Human genes 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 229960000575 trastuzumab Drugs 0.000 claims 2
- 125000006528 (C2-C6) alkyl group Chemical group 0.000 claims 1
- 125000006781 (C4-C10) cycloalkylcarbonyl group Chemical group 0.000 claims 1
- 206010000830 Acute leukaemia Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 210000000170 cell membrane Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- 201000002740 oral squamous cell carcinoma Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 claims 1
- 229960002087 pertuzumab Drugs 0.000 claims 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14305621 | 2014-04-25 | ||
| EP14305621.6 | 2014-04-25 | ||
| PCT/EP2015/059052 WO2015162293A1 (en) | 2014-04-25 | 2015-04-27 | Antibody-drug-conjugate and its use for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017513904A JP2017513904A (ja) | 2017-06-01 |
| JP2017513904A5 true JP2017513904A5 (enExample) | 2018-05-17 |
| JP6567551B2 JP6567551B2 (ja) | 2019-08-28 |
Family
ID=50630737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016564173A Active JP6567551B2 (ja) | 2014-04-25 | 2015-04-27 | 抗体−薬物複合体および癌の処置のためのその使用 |
Country Status (22)
| Country | Link |
|---|---|
| US (5) | US10314921B2 (enExample) |
| EP (2) | EP3607996B1 (enExample) |
| JP (1) | JP6567551B2 (enExample) |
| KR (1) | KR102459647B1 (enExample) |
| CN (1) | CN106470708B (enExample) |
| AU (1) | AU2015250761B2 (enExample) |
| BR (1) | BR112016024363A2 (enExample) |
| CA (1) | CA2946796C (enExample) |
| CY (1) | CY1122472T1 (enExample) |
| DK (1) | DK3134125T3 (enExample) |
| ES (1) | ES2764110T3 (enExample) |
| HR (1) | HRP20192254T1 (enExample) |
| HU (1) | HUE047952T2 (enExample) |
| LT (1) | LT3134125T (enExample) |
| MX (1) | MX378281B (enExample) |
| PL (1) | PL3134125T3 (enExample) |
| PT (1) | PT3134125T (enExample) |
| RS (1) | RS59799B1 (enExample) |
| RU (1) | RU2685259C2 (enExample) |
| SI (1) | SI3134125T1 (enExample) |
| WO (1) | WO2015162293A1 (enExample) |
| ZA (1) | ZA201607415B (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9758591B2 (en) | 2012-08-24 | 2017-09-12 | The Regents Of The University Of California | Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis |
| FR3005051A1 (fr) * | 2013-04-25 | 2014-10-31 | Pf Medicament | Derives de la dolastatine 10 et d'auristatines |
| BR112016024619A2 (pt) | 2014-04-25 | 2017-10-10 | Pf Medicament | conjugado de anticorpo ao igf-1r-fármaco e seu uso para o tratamento de câncer |
| HUE047952T2 (hu) | 2014-04-25 | 2020-05-28 | Pf Medicament | Ellenanyag-drog konjugátum és alkalmazása rák kezelésében történõ alkalmazásra |
| US9808528B2 (en) | 2014-06-18 | 2017-11-07 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates and methods of using same |
| TWI695011B (zh) | 2014-06-18 | 2020-06-01 | 美商梅爾莎納醫療公司 | 抗ｈｅｒ２表位之單株抗體及其使用之方法 |
| WO2016001485A1 (en) | 2014-06-30 | 2016-01-07 | Glykos Finland Oy | Saccharide derivative of a toxic payload and antibody conjugates thereof |
| EP3288593A1 (en) * | 2015-04-27 | 2018-03-07 | Pierre Fabre Médicament | Conjugate of monomethyl auristatin f and trastuzumab and its use for the treatment of cancer |
| JP6968790B2 (ja) | 2015-10-26 | 2021-11-17 | ピエール、ファーブル、メディカマン | Ｉｇｆ−１ｒ発現癌の処置のための組成物 |
| US9669106B2 (en) * | 2015-10-26 | 2017-06-06 | Pierre Fabre Medicament | Conjugate of monomethyl auristatin F and trastuzumab and its use for the treatment of cancer |
| EP3421463A4 (en) * | 2016-02-26 | 2019-10-23 | Jiangsu Hengrui Medicine Co., Ltd. | NEW TOXIN AND METHOD FOR PRODUCING AN INTERMEDIATE PRODUCT THEREOF |
| JOP20170053B1 (ar) * | 2016-03-02 | 2021-08-17 | Eisai Randd Man Co Ltd | مترافقات جسم مضاد وعقار أساسها إيريبولين وطرق استخدامها |
| CN105968038A (zh) * | 2016-05-09 | 2016-09-28 | 湖北华世通生物医药科技有限公司 | 二肽类化合物的盐酸盐及其制备方法 |
| MX2018016330A (es) | 2016-06-27 | 2020-02-17 | Univ California | Combinaciones para tratamiento del cáncer. |
| JP7050770B2 (ja) | 2016-10-05 | 2022-04-08 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 抗体薬物コンジュゲートの調製方法 |
| MX2019010804A (es) | 2017-03-15 | 2020-01-23 | Silverback Therapeutics Inc | Compuestos de benzazepina, conjugados y usos de los mismos. |
| CN111065653A (zh) * | 2017-05-23 | 2020-04-24 | 中央研究院 | 藉由预靶向的双特异性聚乙二醇结合抗体将聚乙二醇化试剂条件性内吞用于诊断和治疗 |
| US20210079039A1 (en) * | 2018-04-16 | 2021-03-18 | Avelas Biosciences, Inc. | Compositions and methods for the selective delivery of therapeutic and imaging agents |
| CN119055787A (zh) | 2018-05-11 | 2024-12-03 | 四川科伦博泰生物医药股份有限公司 | 抗her2抗体-药物偶联物在治疗癌症中的用途 |
| KR102858995B1 (ko) | 2018-09-27 | 2025-09-11 | 피에르 파브르 메디카먼트 | 설포말레이미드계 링커 및 상응하는 컨쥬게이트 |
| AU2019350466A1 (en) * | 2018-09-28 | 2021-04-29 | Pierre Fabre Medicament | New immunocytokines for the treatment of cancer |
| EP3735991A1 (fr) * | 2019-05-06 | 2020-11-11 | Pierre Fabre Medicament | Adc pour un traitement concomitant ou postérieur au docétaxel |
| EP4106819A1 (en) | 2020-02-21 | 2022-12-28 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
| IL299508A (en) | 2020-07-01 | 2023-02-01 | Ars Pharmaceuticals Inc | Anti-asgr1 antibody conjugates and uses thereof |
| CN116438200A (zh) | 2020-09-10 | 2023-07-14 | 普雷西里克斯公司 | 针对fap的抗体片段 |
| KR20230158005A (ko) | 2021-03-18 | 2023-11-17 | 씨젠 인크. | 생물학적 활성 화합물의 내재화된 접합체로부터의 선택적 약물 방출 |
| WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
| JP2025517625A (ja) | 2022-05-02 | 2025-06-10 | プレシリックス・ナームローゼ・ベンノートシヤープ | プレターゲティング |
| CN118307677B (zh) * | 2023-01-09 | 2025-08-12 | 中国医学科学院医药生物技术研究所 | 一种针对间皮素的单克隆抗体及应用 |
| WO2025087401A1 (zh) * | 2023-10-27 | 2025-05-01 | 四川科伦博泰生物医药股份有限公司 | 稠环化合物及其制备方法和用途 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| CA2173150C (en) | 1993-10-01 | 2004-11-30 | Kyoichi Sakakibara | Novel peptide derivatives |
| US7241444B2 (en) * | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
| KR101270829B1 (ko) | 2004-09-23 | 2013-06-07 | 제넨테크, 인크. | 시스테인 유전자조작 항체 및 접합체 |
| EP1940470B1 (en) | 2005-09-26 | 2013-04-17 | Medarex, Inc. | Antibody-drug conjugates and their use |
| US20090098115A1 (en) * | 2006-10-20 | 2009-04-16 | Lisa Michele Crocker | Cell lines and animal models of HER2 expressing tumors |
| CN101573384B (zh) * | 2006-10-27 | 2013-02-20 | 健泰科生物技术公司 | 抗体和免疫偶联物及其用途 |
| WO2008079849A2 (en) | 2006-12-22 | 2008-07-03 | Genentech, Inc. | Antibodies to insulin-like growth factor receptor |
| AR065803A1 (es) * | 2007-03-23 | 2009-07-01 | Smithkline Beecham Corp | Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento |
| AR066476A1 (es) | 2007-05-08 | 2009-08-19 | Genentech Inc | Anticuerpos anti-muc16 disenados con cisteina y conjugaods de anticuerpos y farmacos |
| CA2698541C (en) | 2007-10-19 | 2018-01-09 | Genentech, Inc. | Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates |
| DK2265283T3 (da) * | 2008-03-18 | 2014-10-20 | Seattle Genetics Inc | Auristatin-lægemiddel-linker-konjugater |
| KR101674097B1 (ko) | 2008-04-11 | 2016-11-08 | 시애틀 지네틱스, 인크. | 췌장, 난소 및 다른 암의 검출 및 치료 |
| EP2403524A4 (en) | 2009-03-06 | 2012-09-26 | Agensys Inc | CONJUGATES ANTIBODY-DRUG (ADC) BINDING PROTEINS 24P4C12 |
| WO2010146059A2 (en) | 2009-06-16 | 2010-12-23 | F. Hoffmann-La Roche Ag | Biomarkers for igf-1r inhibitor therapy |
| AR080793A1 (es) | 2010-03-26 | 2012-05-09 | Roche Glycart Ag | Anticuerpos biespecificos |
| WO2011130598A1 (en) | 2010-04-15 | 2011-10-20 | Spirogen Limited | Pyrrolobenzodiazepines and conjugates thereof |
| CN103200950B (zh) | 2010-06-10 | 2016-03-16 | 西雅图基因公司 | 新颖的耳他汀衍生物及其用途 |
| ES2553874T3 (es) | 2010-09-29 | 2015-12-14 | Seattle Genetics, Inc. | N-Carboxialquil-auristatinas y su uso |
| CA2815363C (en) * | 2010-10-22 | 2020-07-14 | Seattle Genetics, Inc. | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway |
| CA2813411C (en) | 2010-11-05 | 2016-08-02 | Rinat Neuroscience Corporation | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| JP6023097B2 (ja) | 2011-03-16 | 2016-11-09 | シアトル ジェネティックス， インコーポレイテッド | Ｎカルボキシアルキルオーリスタチンおよびその使用 |
| US9150644B2 (en) | 2011-04-12 | 2015-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II |
| EP2714685B1 (en) * | 2011-05-27 | 2016-10-19 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives |
| KR102179369B1 (ko) | 2011-05-27 | 2020-11-16 | 암브룩스, 인코포레이티드 | 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도 |
| US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| EP2589609A1 (en) | 2011-11-03 | 2013-05-08 | Pierre Fabre Medicament | Antigen binding protein and its use as addressing product for the treatment of cancer |
| KR102143664B1 (ko) | 2012-06-07 | 2020-08-11 | 암브룩스, 인코포레이티드 | 전립선 특이적 막 항원 항체 약물 접합체 |
| ES2718478T3 (es) * | 2012-06-08 | 2019-07-02 | Sutro Biopharma Inc | Anticuerpos que comprenden restos de aminoácidos no naturales de localización específica, métodos para su preparación y métodos para su uso |
| SG11201408494UA (en) | 2012-06-19 | 2015-02-27 | Ambrx Inc | Anti-cd70 antibody drug conjugates |
| US20140017265A1 (en) | 2012-07-05 | 2014-01-16 | Mersana Therapeutics, Inc. | Terminally Modified Polymers and Conjugates Thereof |
| AU2013302273A1 (en) * | 2012-08-14 | 2015-02-19 | Angiochem Inc. | Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin |
| US20150314007A1 (en) | 2012-12-21 | 2015-11-05 | Glykos Finland Oy | Linker-payload molecule conjugates |
| FR3005051A1 (fr) * | 2013-04-25 | 2014-10-31 | Pf Medicament | Derives de la dolastatine 10 et d'auristatines |
| HUE047952T2 (hu) | 2014-04-25 | 2020-05-28 | Pf Medicament | Ellenanyag-drog konjugátum és alkalmazása rák kezelésében történõ alkalmazásra |
-
2015
- 2015-04-27 HU HUE15720314A patent/HUE047952T2/hu unknown
- 2015-04-27 MX MX2016013999A patent/MX378281B/es unknown
- 2015-04-27 RS RS20191700A patent/RS59799B1/sr unknown
- 2015-04-27 HR HRP20192254TT patent/HRP20192254T1/hr unknown
- 2015-04-27 BR BR112016024363A patent/BR112016024363A2/pt not_active Application Discontinuation
- 2015-04-27 PT PT157203142T patent/PT3134125T/pt unknown
- 2015-04-27 RU RU2016145445A patent/RU2685259C2/ru active
- 2015-04-27 EP EP19195042.7A patent/EP3607996B1/en active Active
- 2015-04-27 AU AU2015250761A patent/AU2015250761B2/en not_active Ceased
- 2015-04-27 KR KR1020167031822A patent/KR102459647B1/ko active Active
- 2015-04-27 WO PCT/EP2015/059052 patent/WO2015162293A1/en not_active Ceased
- 2015-04-27 LT LTEP15720314.2T patent/LT3134125T/lt unknown
- 2015-04-27 JP JP2016564173A patent/JP6567551B2/ja active Active
- 2015-04-27 PL PL15720314T patent/PL3134125T3/pl unknown
- 2015-04-27 US US15/306,404 patent/US10314921B2/en active Active
- 2015-04-27 ES ES15720314T patent/ES2764110T3/es active Active
- 2015-04-27 SI SI201531056T patent/SI3134125T1/sl unknown
- 2015-04-27 CA CA2946796A patent/CA2946796C/en active Active
- 2015-04-27 DK DK15720314.2T patent/DK3134125T3/da active
- 2015-04-27 EP EP15720314.2A patent/EP3134125B1/en active Active
- 2015-04-27 CN CN201580034144.1A patent/CN106470708B/zh active Active
-
2016
- 2016-10-27 ZA ZA2016/07415A patent/ZA201607415B/en unknown
-
2018
- 2018-01-31 US US15/885,220 patent/US10912841B2/en active Active
-
2019
- 2019-04-16 US US16/385,597 patent/US11219693B2/en active Active
- 2019-12-20 CY CY20191101344T patent/CY1122472T1/el unknown
-
2020
- 2020-10-28 US US17/083,010 patent/US11517625B2/en active Active
-
2021
- 2021-11-15 US US17/454,931 patent/US11918656B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017513904A5 (enExample) | ||
| RU2016145445A (ru) | Конъюгат антитела и лекарственного средства и его применение для лечения рака | |
| JP2017513900A5 (enExample) | ||
| Safarzadeh Kozani et al. | Nanobody-based CAR-T cells for cancer immunotherapy | |
| RU2016145444A (ru) | Конъюгат антитела против igf-1r с лекарственным средством и его применение для лечения рака | |
| IL295759A (en) | Transglutaminase mediated coupling | |
| JP2017522871A5 (enExample) | ||
| AU2016293606A1 (en) | Cysteine-substituted immunoglobulins | |
| ME02369B (me) | Antitela za terapiju kancera koji eksprimira klaudin 6 | |
| JP2019509055A5 (enExample) | ||
| IL278633B2 (en) | Immunoconjugates | |
| JP2017537620A5 (enExample) | ||
| IL317587A (en) | Antibody against SIRPalpha | |
| JP2017186337A5 (enExample) | ||
| JP2013505944A5 (enExample) | ||
| JP2023113685A (ja) | 抗体－ａｌｋ５阻害剤コンジュゲートおよびその使用 | |
| JP2011046732A5 (enExample) | ||
| JP2014522850A5 (enExample) | ||
| JP2016098233A5 (enExample) | ||
| EP3880712A1 (en) | MONOCLONAL ANTIBODIES AGAINST IgV DOMAIN OF B7-H3 AND USES THEREOF | |
| SI2582728T1 (en) | Human Antibodies Conjugates against a Tissue Factor | |
| RU2017118225A (ru) | Антитела к PD-1 и способы их применения | |
| JP2011519864A5 (enExample) | ||
| JP2015509947A5 (enExample) | ||
| JP2020502271A5 (enExample) |